Invo BioScience Return on Tangible Equity 2010-2024 | NAYA
Current and historical return on tangible equity values for Invo BioScience (NAYA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Invo BioScience Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.01B |
$-0.01B |
75.68% |
| 2024-03-31 |
$-0.01B |
$-0.01B |
90.32% |
| 2023-12-31 |
$-0.01B |
$-0.01B |
152.38% |
| 2023-09-30 |
$-0.01B |
$-0.01B |
276.92% |
| 2023-06-30 |
$-0.01B |
$-0.00B |
2200.00% |
| 2023-03-31 |
$-0.01B |
$0.00B |
-1600.00% |
| 2022-12-31 |
$-0.01B |
$-0.00B |
-600.00% |
| 2022-09-30 |
$-0.01B |
$0.00B |
-225.00% |
| 2022-06-30 |
$-0.01B |
$0.00B |
-188.24% |
| 2022-03-31 |
$-0.01B |
$0.01B |
-155.56% |
| 2021-12-31 |
$-0.01B |
$0.01B |
-133.33% |
| 2021-09-30 |
$-0.01B |
$0.00B |
-235.29% |
| 2021-06-30 |
$-0.01B |
$0.00B |
-363.64% |
| 2021-03-31 |
$-0.01B |
$0.01B |
-1200.00% |
| 2020-12-31 |
$-0.01B |
$0.01B |
533.33% |
| 2020-09-30 |
$-0.01B |
$-0.00B |
125.00% |
| 2020-06-30 |
$-0.00B |
$-0.00B |
100.00% |
| 2020-03-31 |
$-0.00B |
$-0.00B |
80.00% |
| 2019-12-31 |
$-0.00B |
$-0.00B |
57.14% |
| 2019-09-30 |
$-0.00B |
$-0.00B |
61.54% |
| 2019-06-30 |
$-0.00B |
$-0.00B |
30.77% |
| 2019-03-31 |
$-0.00B |
$-0.00B |
85.71% |
| 2018-12-31 |
$-0.00B |
$-0.00B |
75.00% |
| 2018-09-30 |
$-0.00B |
$-0.00B |
44.44% |
| 2018-06-30 |
$-0.00B |
$-0.00B |
42.11% |
| 2018-03-31 |
$0.00B |
$-0.01B |
0.00% |
| 2017-12-31 |
$0.00B |
$-0.01B |
0.00% |
| 2017-09-30 |
$0.00B |
$-0.01B |
0.00% |
| 2017-06-30 |
$0.00B |
$-0.01B |
0.00% |
| 2017-03-31 |
$-0.00B |
$-0.01B |
22.22% |
| 2016-12-31 |
$-0.00B |
$-0.01B |
23.53% |
| 2016-09-30 |
$-0.00B |
$-0.00B |
25.00% |
| 2016-06-30 |
$-0.00B |
$-0.00B |
33.33% |
| 2016-03-31 |
$-0.00B |
$-0.00B |
200.00% |
| 2015-12-31 |
$-0.00B |
$-0.00B |
400.00% |
| 2015-09-30 |
$-0.00B |
|
533.33% |
| 2015-06-30 |
$-0.00B |
|
266.67% |
| 2015-03-31 |
$0.00B |
|
0.00% |
| 2011-12-31 |
$0.00B |
$-0.00B |
0.00% |
| 2011-09-30 |
$0.00B |
$-0.00B |
0.00% |
| 2011-06-30 |
$0.00B |
$-0.00B |
0.00% |
| 2011-03-31 |
$0.00B |
$-0.00B |
0.00% |
| 2010-12-31 |
$0.00B |
$-0.00B |
-44.44% |
| 2010-09-30 |
$0.00B |
$-0.00B |
-44.44% |
| 2010-06-30 |
$-0.00B |
$-0.00B |
66.67% |
| 2010-03-31 |
$-0.00B |
$-0.00B |
66.67% |
| 2009-12-31 |
$-0.00B |
$-0.00B |
145.45% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.004B |
$0.003B |
|
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
|
